Bone Metastasis in Solid Tumors Market to Grow Substantially During the Forecast Period (2022-32) – DelveInsight | Key Companies – Actuate Therapeutics, Exelixis, Bayer, Amgen

November 16 19:42 2022
Bone Metastasis in Solid Tumors Market to Grow Substantially During the Forecast Period (2022-32) - DelveInsight | Key Companies - Actuate Therapeutics, Exelixis, Bayer, Amgen
Delveinsight Business Research LLP
As per DelveInsight, the Bone Metastasis In Solid Tumors market size is anticipated to increase in the coming years owing to the rising cases of bone metastasis in solid tumors in the 7MM, the growth in healthcare spending, and the launch of new therapies for bone metastasis treatment in the market.

DelveInsight’s “Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Bone Metastasis in Solid Tumors market size, share, and trends in the United States, EU5 (i.e., the UK, Italy, Spain, Germany, France), and Japan.

The Bone Metastasis in Solid Tumors market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Bone Metastasis in Solid Tumors Market

Bone Metastasis in Solid Tumors: An Overview

Bone metastasis occurs when cancer cells spread from their original site to a bone. Nearly all types of cancer can spread (metastasize) to the bones. But some types of cancer are particularly likely to spread to the bone, including breast cancer and prostate cancer.  The development of bone metastases can be considered in several stages: colonization, quiescence, and progression, either locally leading to overt metastasis in bone or dissemination to another site.

Bone metastasis is common and is one of the leading causes of complications in the natural history of cancer. The consequences of bone metastasis may compromise the quality of life, limit day-to-day activities, threaten life expectancy, and increase medical intervention and expenses. The complications of bone metastases, usually referred to as skeletal-related events (SREs) include pain, hypercalcemia, bone fractures, and nerve compression that may require radiation therapy (RT) or surgery.

Bone Metastasis in Solid Tumors Market Key Facts

  • As per DelveInsight, the Bone Metastasis in Solid Tumors Market size in the United States was found to be USD 1,713.6 million in 2020, which is expected to grow immensely in the coming years. 

  • The total diagnosed prevalent population of Bone Metastasis in Solid Tumors in the US was estimated to be 369,300+ cases in 2020.

  • Currently, pipeline products for Bone metastasis in solid tumors are limited, comprising cabozantinib (Exelixis), 9-ING-41 (Actuate Therapeutics), and others. It is expected that, if launched, these drugs would expand market size during the forecast period.

  • Metastatic bone disease is frequently observed in particular cancer types, especially in metastasis arising from the breast (70%), prostate (85%), lung (40%), and kidney (40%) cancer types (Coleman et al., 2020).

  • According to the American Cancer Society (ACS), about 400,000 new cases of malignant bone metastasis are diagnosed in the United States each year.

Bone Metastasis in Solid Tumors Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Bone Metastasis in Solid Tumors market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Bone Metastasis in Solid Tumors market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Bone Metastasis in Solid Tumors Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the United States from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Bone Metastasis in Solid Tumors Epidemiology Segmented by –

  • Diagnosed Prevalence of Bone Metastatic in Solid Tumors

  • Cases of Bone Metastasis by Solid Tumor type

Bone Metastasis in Solid Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bone Metastasis in Solid Tumors market or expected to get launched during the study period. The analysis covers the Bone Metastasis in Solid Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bone Metastasis in Solid Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Bone Metastasis in Solid Tumors Market Will Evolve by 2032 @ 

https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market

Bone Metastasis in Solid Tumors Therapeutics Analysis

Although treatment of bone metastases is rarely curative, disease control is often possible for many years by using systemic anticancer treatments on a background of multidisciplinary supportive care. This care includes bone-targeted agents such as bisphosphonates or denosumab to inhibit tumor-associated osteolysis and prevent skeletal morbidity and the use of appropriate local treatments such as radiation therapy, orthopedic surgery, and specialist palliative care to minimize the impact of metastatic bone disease on physical functioning.

Some of the key companies in the Bone Metastasis in Solid Tumors Therapeutics Market include:

  • Actuate Therapeutics

  • Exelixis

  • Bayer HealthCare Pharmaceuticals

  • Amgen

And many others

Bone Metastasis in Solid Tumors Drugs Covered in the report include:

  • Cabozantinib (Exelixis)

  • 9-ING-41 (Actuate Therapeutics)

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Bone Metastasis in Solid Tumors Competitive Intelligence Analysis

4. Bone Metastasis in Solid Tumors Market Overview at a Glance

5. Bone Metastasis in Solid Tumors Disease Background and Overview

6. Bone Metastasis in Solid Tumors Patient Journey

7. Bone Metastasis in Solid Tumors Epidemiology and Patient Population 

8. Bone Metastasis in Solid Tumors Treatment Algorithm, Current Treatment, and Medical Practices

9. Bone Metastasis in Solid Tumors Unmet Needs

10. Key Endpoints of Bone Metastasis in Solid Tumors Treatment

11. Bone Metastasis in Solid Tumors Marketed Products

12. Bone Metastasis in Solid Tumors Emerging Drugs and Latest Therapeutic Advances

13. Bone Metastasis in Solid Tumors Market Analysis

14. Attribute Analysis

15. Bone Metastasis in Solid Tumors Market Outlook 

16. Bone Metastasis in Solid Tumors Access and Reimbursement Overview

17. KOL Views on the Bone Metastasis in Solid Tumors Market

18. Bone Metastasis in Solid Tumors Market Drivers

19. Bone Metastasis in Solid Tumors Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/